A Phase II clinical trial to evaluate BA3021 in combination with a PD-1 inhibitor in platinum-resistant ovarian cancer
Latest Information Update: 19 May 2021
At a glance
- Drugs Ozuriftamab vedotin (Primary) ; Programmed cell death 1 receptor antagonists
- Indications Ovarian cancer
- Focus Therapeutic Use
- 19 May 2021 New trial record
- 12 May 2021 According to BioAtla media release, this trial is under review by Health Canada.